NovoCure Ltd. NVCR 深 滬
等待開盤 06-25 09:30:00 美东时间
14.9656
+0.836
+5.91%
華盛通- 最 高15.11
- 今 開14.17
- 成交量 84.94万股
- 最 低 14.17
- 昨 收 14.13
- 總市值 173.33万
- 52周最高 18.92
- 市盈率 靜 --
- 換手率 0.73%
- 52周最低 9.82
- 委 比 -53.02%
- 總股本 0.00亿
- 歷史最高 232.76
- 量 比 0.48
- 振 幅 6.65%
- 歷史最低 5.95
- 每 手 1
- 風險率 2.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Novocure's Topline Data From Phase 3 TRIDENT Trial Of Tumor Treating Fields Therapy For Newly Diagnosed Glioblastoma Did Not Demonstrate Statistically Significant Improvement In Primary Endpoint Of Overall Survival
Novocure (NASDAQ:NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM) at the start of chemoradiation (Early Start Arm) compared to initiating TTFields therapy during the...
06-18 19:05
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
美股周涨跌榜 | 净回报超2600%！资管公司潘兴广场上市三日累涨超58%；慧荣科技周涨超52%
累计净回报超2600%！资管公司潘兴广场上市三日累涨超58%；慧荣科技周涨超52%，Q1营收同比翻倍大超预期>>
05-04 18:33
美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
美股夜盘 | NovoCure Ltd.涨27.41%，Impinj, Inc.涨24.95%
NovoCure Ltd.涨27.41%；Impinj, Inc.涨24.95%；Atlassian涨23.36%
05-01 15:01
美股夜盘 | NovoCure Ltd.涨27.41%，Twilio涨25.18%
NovoCure Ltd.涨27.41%；Twilio涨25.18%；Impinj, Inc.涨24.95%
05-01 13:01
美股夜盘 | NovoCure Ltd.涨26.15%，Twilio涨24.20%
NovoCure Ltd.涨26.15%；Twilio涨24.20%；MYR集团涨23.49%
05-01 10:01
NovoCure shares are trading higher after the company reported better-than-expected Q1 sales results and raised its FY26 sales guidance with its midpoint above estimates.
NovoCure shares are trading higher after the company reported better-than-expec...
04-30 21:26
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript
NovoCure (NASDAQ:NVCR) released first-quarter financial results and hosted an e...
04-30 21:09
NovoCure Raises FY2026 Sales Guidance from $675.000M-$705.000M to $690.000M-$710.000M vs $692.115M Est
NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $675.000 million-$705.000 million to $690.000 million-$710.000 million vs $692.115 million estimate.
04-30 19:32
